SKB264 alone or combined for advanced HER2- breast cancer
Part of Cancer clinical trials.
This study is a real-world treatment trial for people with advanced HER2-negative breast cancer (either triple-negative or HR+/HER2-). It tests a drug called SKB264, given alone or with other therapies, and aims to see how well it works in everyday clinical practice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have either triple-negative breast cancer (HER2-, ER-, PR-) or HR+/HER2- breast cancer (hormone-receptor-positive and HER2-negative).
- Your cancer is locally advanced and cannot be removed by surgery, or has spread to other parts of the body (metastatic).
- For triple-negative breast cancer: you have had 2 or fewer prior treatments for advanced disease. For HR+/HER2- breast cancer: you have had 2 or fewer prior chemotherapies or targeted therapies (hormone therapy doesn't count).
- You are not pregnant or breastfeeding.
- You have not had another cancer (except certain skin cancers or cervical cancer) in the past 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SKB264 for people with a common type of breast cancer (HR+/HER2-) that has spread or come back and has not responded to at least one round of chemotherapy. It aims to see if this treatment can help shrink tumors or slow the disease.
This trial tests a new drug, SKB264, against standard chemotherapy for people with a common type of breast cancer (HR+/HER2-) that has spread and stopped responding to hormone therapy. It may offer a new option if you haven't had chemotherapy for advanced disease.
This trial tests a new drug, SKB103, for people with HER2-negative breast cancer that has not responded to standard treatments. The goal is to see if the drug can help shrink tumors or slow the cancer's growth.
This trial tests a new drug called SKB264 against standard chemotherapy options for people with advanced triple-negative breast cancer who have not yet received chemotherapy for their advanced disease. The goal is to see if SKB264 works better than the usual treatments.
This trial is testing a combination of two targeted therapies, SKB264 and Inetetamab, for people with advanced HER2-positive breast cancer that has kept growing after treatment with T-DXd and other HER2-targeted therapies. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
This study tests SKB565, a new injectable cancer treatment, in people with advanced solid tumors (cancer that has spread or hasn't responded to standard treatments). The trial aims to find the right dose and learn how well it works.
Hear when a new HER2-negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.